Cerecin produces Ketasyn which is a molecule for Alzheimer's, Parkinson's, and other age associated memory impairments. The company was founded by Mark Heiman, Samuel Henderson, and Steve Orndorff in 2001, in Denver, Colorado, United States.
The company looks to understand core molecular and cellular processes that contribute to brain development, plasticity, function, and aging.
As of 2020, Cerecin is developing Tricapilin. Tricapilin is an investigational drug for neurological conditions that is meant to assist with Alzheimer's Disease, migraines, Parkinson's Disease, and epilepsy's.
Some of the companies and partners the company works with includes DCB duchembio, Nestle Health Science, Nestle PURINA, wilmar, and EDB Singapore.
Timeline
Funding rounds
People
Bruce Marimoto
VP of drug development
Charles Stacey
CEO
Jerris Knaisch
Finance
Judy Walker
CMO
Sam Henderson
CSO
Further reading
Documentaries, videos and podcasts
Companies
Accera
Denver, Colorado, United States
Drug Development
News
References
CompanyCompany attributes
Biomedical engineering
Brain–computer interface
Denver
Singapore
MelbourneOther attributes
United StatesCategories
Related Topics
Contributors
- 1
Daniel Frumkin
Mechanical engineering, cryptocurrencies, AI, and travel. - 2
Carla Faraguna
Golden People and Operations. - 3
Rebecca Hammond
MA English I HDip Psychology - Following AI, behavioural and educational psychology - 4
Erin Scherfner
loading information... - 5
Keeri Tramm
Accomplished manager, brand communicator, and burgeoning data analyst. - 6
Wyckliffe Otieno
Dedicated information technology enthusiast. - 7
Henry Ogolla
Passionate about reading and writing.